Proactive Investors - Run By Investors For Investors

Horizon Discovery strikes immuno-oncology JV

Horizon Discovery is to form a new joint venture called Avvinity Therapeutics in a bid to target an immuno-oncology market currently worth £25bn a year.
Horizon Discovery strikes immuno-oncology JV
The new venture is targeting an immuno-oncology market currently worth £25bn a year

Horizon Discovery (LON:HZD) is to form a new joint venture called Avvinity Therapeutics in a bid to target an immuno-oncology market currently worth £25bn a year.

The venture is with UK based biotech Centauri Therapeutics and will combine Horizon's gene editing, immunology, oncology and drug discovery capabilities with Centauri's Alphamer technology to  develop therapeutics for solid tumours and leukaemias.

Dr Darrin M. Disley' chief executive of Horizon, told investors: "By combining Horizon's deep understanding of the genetic basis of cancer alongside its gene editing, drug discovery and emerging immuno-oncology toolbox, with Centauri's unique Alphamer technology and knowledge of its use, we have created an exciting new company to spearhead Horizon's move into targeted therapeutic development."

Under the terms,  Horizon will out-license certain intellectual property (IP) relating to its translational genomics and drug discovery platforms, and will invest up to £5.3 million over two tranches.

The first tranche  of £2.5mln has been committed, and the second will be at Horizon's discretion pending the progress of three development programmes.

Centauri will license background IP and expertise on its Alphamer technology to Avvinity, which will have exclusivity for the field of oncology for an initial three years, which can be extended.

Neither Horizon nor Centauri have to provide further funding to Avvinity, though both may choose to participate in future funding rounds. Subject to achieving key development milestones, Avvinity plans to raise new external investment to take its innovative drugs into clinical trials, at which time the value of Horizon's stake in the business would be highly-material, the firm pointed out.

The move is part of Horizon's strategy to invest up to £10 million, further leveraged by its IP, technology platforms and know-how, to identify the next generation of molecular and cellular cancer therapeutics.


Why Invest In Horizon Discovery Group PLC? Read More Here

Register here to be notified of future HZD Company articles
View full HZD profile

Horizon Discovery Group PLC Timeline

September 20 2016
Big Picture
September 13 2016
September 06 2016

Related Articles

Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.
July 26 2016
Chief executive Cameron Reynolds told Proactive: "It's one thing to be a science project. It's another to have products and we are right on the cusp of that.”

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.